Monday, March 1, 2010

When's The Next Nintendo Event

ALMIRALL. PHARMACEUTICAL TO WATCH.

end of November 2009 began the series of comments about this company. The 25 / 2 last published the results of 2009, being the reason I moved to update the comment.

Considering the published data and daily cap 24 / 2, would have the following ratios:

1) PER slightly above 11 times.

2) EV / EBITDA in the 6.8 environment.

3) The capitalization is just over 8 times free cash flow.

From my p. of v. remain in force the comments he made last November, adding however: "Interesting

disiminución of commercial and administrative expenses but everything has a limit.

-Rationalization of production decreasing the number of plants.


-Growth in sales in 9 of the 10 most important products it sells. If we mean business areas in all major growing less in the nervous system.
Moreover
indicates that society expects similar numbers in 2010.

therefore nothing to show to the comments in November on the potential investment interest, just note that since then it has risen by about 10% deducted from both the margin of safety. Several readers have made

0 comments:

Post a Comment